WEE1 kinase has been reported to be aberrantly expressed in melanomas, glioblastoma multiforme (GBMs), triple negative breast cancers (TNBCs) and some prostate cancers. Dependence of various cancer cells on WEE1 signaling suggests that targeting epigenentic activity of WEE1 is a viable strategy for overcoming tumor proliferation.

Recently, we designed an assay that provides specific and quantitative measure of WEE1 epigenetic activity. Using this assay, we have identified a new class of WEE1 inhibitors that specifically suppress WEE1 epigenetic activity.   

Translational Research